Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.

Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.

Oct 28, 2024

BIG PHARMA EARNINGS WATCH: ROCHE AND SANOFI

Big Pharma Giants Continue Reporting Expectation-Beating Q3 Earnings After Maintaining

Oct 23, 2024

SECOND OPINION: BIG PHARMA ONCE AGAIN TRIES TO DEFEND THE PATENT ABUSE STATUS QUO

Eli Lilly Opinion Column Reiterates Debunked Arguments on Innovation as Brand Name Drug

Oct 17, 2024

BIG PHARMA EARNINGS: JOHNSON & JOHNSON

Johnson & Johnson Reports Higher-Than-Expected Earnings Fueled by Price Hikes This

Oct 10, 2024

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1 WEIGHT LOSS DRUG PRICES COULD COST MEDICARE $35 BILLION

CBO Confirms Cost of Blockbuster Obesity Drugs at Current Prices Would Significantly

Oct 28, 2024

BIG PHARMA EARNINGS WATCH: ROCHE AND SANOFI

Big Pharma Giants Continue Reporting Expectation-Beating Q3 Earnings After Maintaining

Oct 23, 2024

SECOND OPINION: BIG PHARMA ONCE AGAIN TRIES TO DEFEND THE PATENT ABUSE STATUS QUO

Eli Lilly Opinion Column Reiterates Debunked Arguments on Innovation as Brand Name Drug

Oct 17, 2024

BIG PHARMA EARNINGS: JOHNSON & JOHNSON

Johnson & Johnson Reports Higher-Than-Expected Earnings Fueled by Price Hikes This

Oct 10, 2024

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1 WEIGHT LOSS DRUG PRICES COULD COST MEDICARE $35 BILLION

CBO Confirms Cost of Blockbuster Obesity Drugs at Current Prices Would Significantly

Videos

Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.

Fact Sheets

Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.

Infographics

Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.

Polling

See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.

Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.

By signing your name, you are opting-in to receive calls and SMS/MMS messages, including autodialed and automated calls and texts, to that number from CSRxP. Msg & data rates may apply.
This field is for validation purposes and should be left unchanged.